Clinical Trial Update: Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nivolumab combined with ifosfamide, carboplatin, and etoposide as second-line therapy for recurrent or refractory Hodgkin lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• OPDIVO (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-09